Peginesatide
![Version 1; Peer Review: 1 Approved, 1 Approved with Reservations]](http://data.docslib.org/img/264x/420c82ddb51fed51a7dca7da7d763649.webp)
Top View
- KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease
- NIOSH Hazardous Drugs Table 1 Antineoplastic Drugs
- NON-ONCOLOGY N = 1919 Distinct NDC N = 244 Distinct Generic
- Erythropoiesis Stimulating Agents: Approaches to Modulate Activity
- OMONTYS (Peginesatide) Injection, Dosage Form Strengths for Intravenous Or Subcutaneous Use Single Use Vials 2 Mg/0.5 Ml, 3 Mg/0.5 Ml, Initial U.S
- Clinical Pharmacology Biopharmaceutics Review(S)
- Erythropoiesis-Stimulating Agents
- Dose-Finding Study of Peginesatide for Anemia Correction in Chronic Kidney Disease Patients Article
- Omontys, INN-Peginesatide
- SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
- Custodians of Medicaid Services Manual From
- Article Peginesatide for Maintenance Treatment of Anemia In
- 2. the Case for Protein Pegylation
- Amgen 2011 Annual Report and Financial Summary
- Profile of Peginesatide and Its Potential for the Treatment of Anemia in Adults with Chronic Kidney Disease Who Are on Dialysis
- Alaska Medicaid Preferred Drug List (PDL)
- Allergen Extracts Prior Authorization Guidelines
- Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012